MedTrace Logo

Rimegepant For Endometriosis Pain

NCT07795125 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2026-08-31

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of rimegepant 75 mg versus placebo in reducing endometriosis-associated pain (EAP) in women with moderate-to-severe pain and histologically confirmed endometriosis.

Conditions

Interventions

DRUG

Rimegepant 75 MG

Rimegepant 75 mg oral capsule administered every other day for 12 weeks

DRUG

Placebo

Matching placebo oral capsule administered every other day for 12 weeks.

Sponsors & Collaborators

Principal Investigators

  • Yohannes Woldeamanuel, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2031-03-30
Completion
2031-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07795125 on ClinicalTrials.gov